Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing
By LabMedica International staff writers Posted on 08 Apr 2020 |
Image: Nova Biomedical adds PT/INR test to Allegro analyzer for POC testing (Photo courtesy of Nova Biomedical)
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.
Nova develops and manufactures whole blood, point-of-care and critical care analyzers, as well as provides advanced instruments for cell culture monitoring to the biotechnology industry. Nova’s Allegro is a compact, fast, and simple POC analyzer that features a clinically important menu of twelve measured and individually selectable tests, plus six calculated tests. All Allegro tests use easy capillary fingerstick sampling, eliminating the need for veni punctures or a trained phlebotomist, and easy-to-use disposable test cartridges or strips. Allegro’s quick six to nine-minute cartridge test times and ability to measure two cartridges simultaneously provide rapid results immediately to the physician, doubling throughput and improving efficiency.
Allegro's companion meters wirelessly transmit results to the analyzer, where they combine with all cartridge test results for one patient report. All results can be transmitted to electronic medical records for providers to review with patients during the visit. Having immediate results during the patient visit reduces clinic follow-up calls, letters, and patient re-visits, and improves patient satisfaction, compliance with care plans, and outcomes.
Allegro is the only analyzer that can measure HbAlc, lipids, glucose, and creatinine from a capillary sample. The latest upgrade now allows Allegroto monitor patient coagulation therapy in addition to testing for glycemic control, kidney function, anemia, gout, and cardiac risk with a full lipids panel. PT/INR is just one of 18 tests for the Allegro platform, including HbA1c, cholesterol, triglycerides, glucose, creatinine, UACR, hemoglobin, hematocrit, and uric acid. The Allegro analyzer and the new PT/INR test are available for purchase in CE-regulated countries.
Related Links:
Nova Biomedical
Nova develops and manufactures whole blood, point-of-care and critical care analyzers, as well as provides advanced instruments for cell culture monitoring to the biotechnology industry. Nova’s Allegro is a compact, fast, and simple POC analyzer that features a clinically important menu of twelve measured and individually selectable tests, plus six calculated tests. All Allegro tests use easy capillary fingerstick sampling, eliminating the need for veni punctures or a trained phlebotomist, and easy-to-use disposable test cartridges or strips. Allegro’s quick six to nine-minute cartridge test times and ability to measure two cartridges simultaneously provide rapid results immediately to the physician, doubling throughput and improving efficiency.
Allegro's companion meters wirelessly transmit results to the analyzer, where they combine with all cartridge test results for one patient report. All results can be transmitted to electronic medical records for providers to review with patients during the visit. Having immediate results during the patient visit reduces clinic follow-up calls, letters, and patient re-visits, and improves patient satisfaction, compliance with care plans, and outcomes.
Allegro is the only analyzer that can measure HbAlc, lipids, glucose, and creatinine from a capillary sample. The latest upgrade now allows Allegroto monitor patient coagulation therapy in addition to testing for glycemic control, kidney function, anemia, gout, and cardiac risk with a full lipids panel. PT/INR is just one of 18 tests for the Allegro platform, including HbA1c, cholesterol, triglycerides, glucose, creatinine, UACR, hemoglobin, hematocrit, and uric acid. The Allegro analyzer and the new PT/INR test are available for purchase in CE-regulated countries.
Related Links:
Nova Biomedical
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus